| ID | 1145 |
| Name of the vaccine | Pneumosil |
| Microbe | Bacteria |
| Disease name | Pneumococcal |
| Name of bacteria | Streptococcus pneumoniae |
| Type of vaccine | Conjugate |
| Nucleic acid content | DNA |
| Age | 6 weeks to 2 years |
| Description of the vaccine | Pneumococcal polysaccharide conjugate Vaccine (10-valent) for serotypes 1, 5, 6A, 6B, 7F, 9V, 14, 19A, 19F and 23F. |
| Name of the manufacturer | By collaboration between Serum Institute of India Pvt Ltd and PATH. |
| Name of the manufacturing country | India |
| Year of manufacture | 2020 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-positive, facultative anaerobic bacteria. |
| Efficacy | NA |
| Vaccine formulation | Sterile suspension as 0.5 and 2.5 mL vial. |
| Dosage | Single 0.5 mL dose. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | Immunization against invasive disease, pneumonia and acute otitis media. |
| Export | NA |
| Approval | WHO prequalified |
| Adjuvant | Aluminium phosphate |
| Repurposing | For pneumococcal infections. |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://pneumosil.com/vaccine/ |
| Other name | NA |
| Additional Links | NA
|